Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 6, 2010, Pages 598-603

  Moss, Richard B ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Allergic bronchopulmonary aspergillosis; amphotericin B; Aspergillus fumigatus; cystic fibrosis; itraconazole; omalizumab; voriconazole

Indexed keywords

ALLERGEN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; GLUCOCORTICOID; IMMUNOGLOBULIN G; ITRACONAZOLE; METHYLPREDNISOLONE; OMALIZUMAB; POSACONAZOLE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGY; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CLINICAL TRIAL; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE TOXICITY; FLUSHING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIVER TOXICITY; MALAISE; MYALGIA; NEUROLOGIC DISEASE; PHOTOSENSITIVITY DISORDER; PREVALENCE; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SEROLOGY; SIDE EFFECT; TORSADE DES POINTES;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; COMORBIDITY; CYSTIC FIBROSIS; GLUCOCORTICOIDS; HUMANS;

EID: 77958113699     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32833e24a6     Document Type: Review

References (71)

1. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:805-826.
2. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art -Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 (Suppl 3):S225-S264; Erratum in Clin Infect Dis 2004; 38:158.
3. Moss RB. Critique of trials in allergic bronchopulmonary aspergilllosis and fungal allergy. Med Mycol 2006; 44:S269-S272.
4. Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870-1884.
5. Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med 2010; 16:242-250.
6. Moss RB. Allergic bronchopulmonary aspergillosis. In: Latge JP, Steinbach WJ, editors. Aspergillus fumigatus and aspergillosis. Washington, DC: American Society of Microbiology Press; 2009 . ; Chapter 26. pp. 333-350.
7. Hohl TM, Feldmesser M. Aspergillus fumigatus: principles of pathogenesis and host defense. Eukaryot Cell 2007; 6:1953-1963. (Pubitemid 350221264)
8. Park SJ, Mehrad B. Innate immunity to Aspergillus species. Clin Microbiol Rev 2009; 22:535-551.
9. Rapaka RR, Kolls JK. Pathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis: current understanding and future directions. Med Mycol 2009; 47 (Suppl 1):S331-S337.
10. Nagano Y, Millar B, Johnson E, et al. Fungal infections in patients with cystic fibrosis. Rev Med Microbiol 2007; 18:11-16. (Pubitemid 47266699)
11. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis: a review. Med Mycol 2009; 47:387-397.
12. Sudfield CF, Dasenbrook EC, Merz WG, et al. Prevalence and risk factors for recovery of filamentous fungi in individual with cystic fibrosis. J Cyst Fibros 2010; 9:110-116.
13. Nagano Y, Millar BC, Goldsmith CE, et al. Development of selective media for the isolation of yeasts and filamentous fungi from the sputum of adult patients with cystic fibrosis. J Cyst Fibros 2008; 7:566-572.
14. Nagano Y, Elborn JS, Millar BC, et al. Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol 2010; 48:166-176.
15. De Valk HA, Klaassen CH, Yntema JB, et al. Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. J Cyst Fibros 2009; 8:110-114.
16. Vanhee LM, Symoens F, Bouchara JP, et al. High-resolution genotyping of Aspergillus fumigatus isolates recovered from chronically colonized patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2008; 27:1005-1007.
17. Shoseyov D, Brownlee KG, Conway SP, et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130:222-226. (Pubitemid 44116864)
18. Kanthan SK, Bush A, Kemp M, et al. Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis. Pediatr Pulmonol 2007; 42:785-793. (Pubitemid 47580805)
19. Amin R, Dupuis A, Aaron SD, et al. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in cystic fibrosis patients. Chest 2010; 137:171-176.
20. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2:29-34. (Pubitemid 36857407)
21. Nicolai T, Arleth S, Spaeth A, et al. Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis. Pediatr Pulmonol 1990; 8:12-15.
22. Milla CE, Wielinski CL, Regelmann WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol 1996; 21:6-10.
23. Wojnarowski C, Eichler I, Gartner C, et al. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis. Am J Respir Crit Care Med 1997; 155:1902-1907. (Pubitemid 27256116)
24. Denning DW, O'Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27:615-626.
25. Denning DW, O'Driscoll BR, Powell G, et al. Randomised controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11-18; Erratum in Am J Respir Crit Care Med 2009; 179:330-331.
26. Pasqualotto AC, Powell G, Niven R, et al. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 2009; 14:1121-1127.
27. Vicencio AG, Muzumdar H, Tsirilakis K, et al. Severe asthma with fungal sensitization in a child: response to itraconazole therapy. Pediatrics 2010; 125:e1255-e1258.
28. Gore RB. The utility of antifungal agents for asthma. Curr Opin Pulm Med 2010; 16:36-41.
29. Casaulta C, Flückiger S, Crameri R, et al. Time course of antibody response to recombinant Aspergillus fumigatus antigens in cystic fibrosis with and without ABPA. Pediatr Allergy Immunol 2005; 16:217-225. (Pubitemid 40638048)
30. Carneiro AC, Lemos AC, Arruda SM, et al. Prevalence of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis in the state of Bahia, Brazil. J Bras Pneumol 2008; 34:900-906.
31. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999; 115:364-370. (Pubitemid 29083042)
32. Chotirmall SH, Branagan P, Gunaratnam C, et al. Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. Respir Care 2008; 53:1035-1041.
33. Kraemer R, Delosé a N, Ballinari P, et al. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211-1220. (Pubitemid 44924822)
34. Hafen GM, Hartl D, Regamey N, et al. Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patients. Expert Rev Mol Diagn 2009; 9:157-164.
35. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of decline of serum IgE levels in allergic bronchopulmonary aspergillosis. Respir Med 2010; 104:204-210.
36. O'Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39:1677-1683.
37. Van Hoeyveld E, Dupont L, Bossuyt X. Quantification of IgG antibodies to Aspergillus fumigatus and pigeon antigens by ImmunoCAP technology: an alternative to the precipitation technique? Clin Chem 2006; 52:1785-1793. (Pubitemid 44330715)
38. Barton RC, Hobson RP, Denton M, et al. Serologic diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus. Diagn Microbiol Infect Dis 2008; 62:287-291.
39. Hemman S, Nikolaizik WH, Schoni MH, et al. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Eur J Immunol 1998; 28:1155-1160.
40. Hemman S, Menz G, Ismail C, et al. Skin test reactivity to 2 recombinant Aspergillus fumigatus allergens in A. fumigatus-sensitized asthmatic subjects allows diagnostic separation of allergic bronchopulmonary aspergillosis from fungal sensitization. J Allergy Clin Immunol 1999; 104:601-607. (Pubitemid 29451650)
41. Kurup VP, Knutsen AP, Moss RB, et al. Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Clin Mol Allergy 2006; 4:11.
42. Almeida MB, Bussamra MH, Rodrigues JC. ABPA diagnosis in cystic fibrosis patients: the clinical utility of IgE specific to recombinant Aspergillus fumigatus allergens. J Pediatr (Rio J) 2006; 82:215-220. (Pubitemid 43894352)
43. Sarfati J, Monod M, Recco P, et al. Recombinant antigens as diagnostic markers for aspergillosis. Diagn Microbiol Infect Dis 2006; 55:279-291. (Pubitemid 44144515)
44. De Oliveira E, Giavina-Bianchi P, Fonseco LA, et al. Allergic bronchopulmonary aspergillosis diagnosis remains a challenge. Respir Med 2007; 101:2352-2357. (Pubitemid 47471403)
45. Glaser AG, Kirsch AI, Zeller S, et al. Molecular and immunological characterization of Asp f34, a novel major cell wall allergen of Aspergillus fumigatus. Allergy 2009; 64:1144-1151.
46. Hartl D, Latzin P, Zissel G, et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 173:1370-1376. (Pubitemid 43900712)
47. Latzin P, Hartl D, Regamey N, et al. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008; 31: 36-42.
48. Moss RB. Management of allergic aspergillosis. Curr Fungal Infect Rep 2008; 2:87-93.
49. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 2000; 16:464-471.
50. Mussafi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25:324-328. (Pubitemid 40246534)
51. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008; 21:580-586.
52. Bolland MJ, Bagg W, Thomas MG, et al. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38:46-49. (Pubitemid 38018004)
53. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009; 49:928-930.
54. Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63:438-450. (Pubitemid 46426628)
55. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4:215-220. (Pubitemid 43013027)
56. Glackin L, Leen G, Elnazir B, et al. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009; 102:29.
57. Pasqualotto AC, Shah M, Wynn R, et al. Voriconazole plasma monitoring. Arch Dis Child 2008; 93:578-581; Erratum in Arch Dis Child 2008; 93:907. (Pubitemid 352030079)
58. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211. (Pubitemid 351269158)
59. Berge M, Guillemain R, Boussaud V, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009; 11:211-219.
60. Howard SJ, Pasqualotto AC, Denning DW. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2010; 16:683-688.
61. Amorim A, Guedes-Vaz L, Araujo R. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonized cystic fibrosis patients receiving azole therapy. Int J Antimicrob Agents 2010; 35:396-399.
62. Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphotericin B. J Aerosol Med Pulm Drug Deliv 2009; 22:213-227.
63. Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung transplant patient successfully treated with nebulized amphotericin. J Heart Lung Transplant 2002; 21:1237-1241. (Pubitemid 35300473)
64. Laoudi Y, Paolini JB, Grimfed A, et al. Nebulized corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 31:908-909.
65. Thomson JM, Wesley A, Byrnes CA, et al. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006; 41:164-170. (Pubitemid 43165446)
66. Cohen-Cymberknoh M, Blau H, Shoseyov D, et al. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J Cyst Fibros 2009; 8:253-257.
67. Van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276-277. (Pubitemid 46579813)
68. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607-610.
69. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43:1249-1251.
70. Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009; 44:516; Erratum in Pediatr Pulmonol 2009; 44:943-944.
71. Brinkmann F, Schwerk N, Hansen G, et al. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2009; 65:134-135.